Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -129.25% is 27% above its 5-year average of -176.51%, near the high end of its 5-year range (-315.72%–-61.51%).
9.02% above its 12-month average of -142.06%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -159.07%.
EBITDA MARGIN
-129.25%
EBITDA MARGIN AVG TTM
-142.06%
EBITDA MARGIN AVG 3Y
-144.94%
EBITDA MARGIN AVG 5Y
-176.51%
EBITDA MARGIN AVG 10Y
-229.57%
EBITDA MARGIN AVG 15Y
-229.57%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+9.02%
CURRENT VS 3Y AVG
+10.82%
CURRENT VS 5Y AVG
+26.77%
CURRENT VS 10Y AVG
+43.70%
CURRENT VS 15Y AVG
+43.70%
CURRENT VS 20Y AVG
N/A
Nuwellis, Inc.
Market Cap
$2.61M
EBITDA Margin
-129.25%
TTM Avg
-142.06%
3Y Avg
-144.94%
5Y Avg
-176.51%
Market Cap
$2.67M
EBITDA Margin
-375.69%
TTM Avg
-244.00%
3Y Avg
-166.51%
5Y Avg
-121.60%
Market Cap
$2.54M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.54M
EBITDA Margin
-372.74%
TTM Avg
-308.17%
3Y Avg
-306.11%
5Y Avg
-396.88%
Market Cap
$2.54M
EBITDA Margin
-163.38%
TTM Avg
-126.27%
3Y Avg
-20964.27%
5Y Avg
-20964.27%
Market Cap
$2.38M
EBITDA Margin
-776.30%
TTM Avg
-1492.64%
3Y Avg
-21514.87%
5Y Avg
-21514.87%
Market Cap
$2.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.31M
EBITDA Margin
-100324.78%
TTM Avg
-75768.79%
3Y Avg
-56097.78%
5Y Avg
-38080.91%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuwellis, Inc. (NUWE) | $2.61M | -129.25% | -142.06% | -144.94% | -176.51% |
| iSpecimen Inc. (ISPC)vs › | $2.67M | -375.69% | -244.00% | -166.51% | -121.60% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.54M | N/A | N/A | N/A | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.54M | -372.74% | -308.17% | -306.11% | -396.88% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -163.38% | -126.27% | -20964.27% | -20964.27% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.45M | N/A | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.38M | -776.30% | -1492.64% | -21514.87% | -21514.87% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.37M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.31M | -100324.78% | -75768.79% | -56097.78% | -38080.91% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.25M | -866.57% | -750.00% | -6212.81% | -4728.90% |
Gross Margin
69.7%
EBITDA Margin
-129.3%
Operating Margin
-140.6%
Net Margin
-123.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -159.07% |
| 2026-03-31 | -180.07% |
| 2025-12-31 | -85.89% |
| 2025-09-30 | -119.71% |
| 2025-06-30 | -165.57% |
| 2025-03-31 | -156.88% |
| 2024-12-31 | -99.22% |
| 2024-09-30 | -61.51% |
| 2024-06-30 | -102.32% |
| 2024-03-31 | -251.64% |
| 2023-12-31 | -136.57% |
| 2023-09-30 | -127.69% |
| 2023-06-30 | -238.02% |
| 2023-03-31 | -315.72% |
| 2022-12-31 | -190.81% |
| 2022-09-30 | -185.23% |
| 2022-06-30 | -189.79% |
| 2022-03-31 | -223.83% |
| 2021-12-31 | -257.37% |
| 2021-09-30 | -276.52% |
| 2021-06-30 | -183.25% |
| 2021-03-31 | -265.48% |
| 2020-12-31 | -203.57% |
| 2020-09-30 | -218.22% |
| 2020-06-30 | -205.80% |
| 2020-03-31 | -276.20% |
| 2019-12-31 | -320.85% |
| 2019-09-30 | -355.27% |
| 2019-06-30 | -260.41% |
| 2019-03-31 | -384.03% |
| 2018-12-31 | -279.85% |
| 2018-09-30 | -307.48% |
| 2018-06-30 | -374.70% |
| 2018-03-31 | -414.66% |
| 2017-12-31 | -845.85% |
| 2017-09-30 | -276.18% |
| 2017-06-30 | -263.66% |
| 2017-03-31 | -232.30% |
| 2016-12-31 | -378.42% |
| 2016-09-30 | -691.90% |
| 2015-03-31 | -11715.25% |
| 2014-12-31 | -3715.82% |
| 2014-09-30 | -10237.29% |
| 2014-03-31 | -10684.75% |
| 2013-09-30 | -10384.75% |
| 2011-09-30 | 8560.00% |
